We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Propofol vs Propofol + Benzo/Opiates in High Risk Group

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01315158
Recruitment Status : Terminated (- The research team is not able to obtain the necessary support to continue the study.)
First Posted : March 15, 2011
Results First Posted : October 28, 2016
Last Update Posted : October 28, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This will be a randomized controlled trial that compares the rates of sedation related complications in high risk patients (ASA greater or equal to 3, BMI greater or equal to 30, those at risk for OSA) undergoing advanced endoscopy procedures with propofol alone compared to propofol in combination with benzodiazepines and opioids.

Condition or disease Intervention/treatment
Sleep Apnea, Obstructive Obesity Drug: Propofol Alone Drug: Propofol+Benzo/Opioids

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Incidence of Sedation Related Complications With Propofol Alone Versus Propofol With Benzodiazepines and Opiates in a High Risk Group Undergoing Advanced Endoscopic Procedures: A Randomized Controlled Trial
Study Start Date : January 2011
Primary Completion Date : July 2014
Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Propofol
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Propofol+Benzo/Opioids

If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:

  1. Recommended Versed:

    a. Prior to intubation

    • patient is < 50 kg = 1 mg Versed
    • patient is 50-75 kg = 1.5 mg Versed
    • patient is > 75 kg = 2 mg Versed
  2. Recommended Fentanyl

    1. Prior to intubation = 0.5 ug/kg
    2. Total procedural dose = 1 ug/kg
Drug: Propofol+Benzo/Opioids
  1. Recommended Versed:

    a. Prior to intubation

    • patient is < 50 kg = 1 mg Versed
    • patient is 50-75 kg = 1.5 mg Versed
    • patient is > 75 kg = 2 mg Versed
  2. Recommended Fentanyl

    1. Prior to intubation = 0.5 ug/kg
    2. Total procedural dose = 1 ug/kg
Other Names:
  • Benzodiazepine
  • Midazolam
  • Versed
  • Opioid
  • Fentanyl
Active Comparator: Propofol Alone

The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:

  • Induction Dose: 2-2.5 mg/kg
  • Maintenance Dose: 0.1-0.2 mg/kg/min
Drug: Propofol Alone

Recommended Propofol doses before considering crossover:

  • Induction: 2-2.5 mg/kg
  • Maintenance: 0.1-0.2 mg/kg/min
Other Names:
  • Propofol
  • Diprivan
  • 2,6-di-isopropofol


Outcome Measures

Primary Outcome Measures :
  1. Number of Participants Who Experience Airway Maneuvers [ Time Frame: One day (during procedure) ]
    In high risk patients (meeting at least of 1 of 3 criteria: ASA ≥ 3, BMI ≥ 30, those at risk for OSA) undergoing advanced endoscopy procedures, compare the number of participants who experience airway maneuvers (AMs) when sedated with propofol alone versus propofol in combination with benzodiazepines and opioids.


Secondary Outcome Measures :
  1. Number of Participants Who Experience Other Sedation Related Complications [ Time Frame: One day (during procedure) ]
    Compare the number of participants who experience other sedation related complications such as hypotension, hypoxemia and need for termination of the procedure between the two groups

  2. Compare Propofol Doses Between the Two Groups [ Time Frame: One day (during procedure) ]
    The dose of propofol used between the two groups will be compared

  3. Predictors of Sedation Related Complications as Measured by the Number of Participants Who Experience Hypoxemia (Defined as a Pulse Oximetry <90% for Any Duration) [ Time Frame: One year ]
  4. Predictors of Sedation Related Complications as Measured by Hypopnea/Apnea (Defined as Fewer Than 6 Breaths/Minute Based on Capnography) [ Time Frame: One year ]
  5. Predictors of Sedation Related Complications as Measured by the Incidences of Hypotension (Defined as Systolic Blood Pressure of Less Than 90mmHg or a Decrease of More Than 25% From Baseline) [ Time Frame: One year ]
  6. Predictors of Sedation Related Complications as Measured by Early Procedure Termination for an Alternative Sedation Related Complication [ Time Frame: One year ]
  7. Patient Tolerance as Assessed by Endoscopists [ Time Frame: 24-48 hours ]
    The frequency of symptoms of nausea and vomiting in the two groups of patients will be recorded. Patient tolerance of the procedure will be assessed independently by the endoscopist using a 100-mm visual analog scale (VAS, 0=unmanageable, 100=excellent). The patient will also score the level of tolerance using the same VAS at a routine follow-up phone call made 24-48 hours after the procedure.

  8. Number of Participants Who Experience Symptoms of Nausea and Vomiting Will be Compared Between the Two Groups [ Time Frame: 24-48 hours ]
    The number of participants who experience symptoms of nausea and vomiting in the two groups of patients will be recorded. This will be recorded during the follow-up phone call made 24-48 hours after the procedure.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to provide informed consent
  • Age greater than or equal to 18 years
  • Presence of at least 1 of the following criteria:

    1. ASA class 3 or higher
    2. BMI of 30 or greater
    3. At risk for OSA (score of 3 or greater on the STOP-BANG screening tool)

Exclusion Criteria:

  • drug allergy to Propofol, Benzodiazepines, or Opioids
  • patients who received Benzodiazepines or Opioids within 24 hours of the procedure
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315158


Locations
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Faris Murad, M.D. Washington University School of Medicine
More Information

Publications:

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01315158     History of Changes
Other Study ID Numbers: 10-1133
First Posted: March 15, 2011    Key Record Dates
Results First Posted: October 28, 2016
Last Update Posted: October 28, 2016
Last Verified: September 2016

Keywords provided by Washington University School of Medicine:
Obstructive Sleep Apnea
Body Mass Index

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Propofol
Midazolam
Fentanyl
Analgesics, Opioid
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Narcotics
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents